We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · January 26, 2022

Modified FOLFIRINOX vs CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
J. Clin. Oncol 2022 Jan 20;40(3)262-271, JM Phelip, J Desrame, J Edeline, E Barbier, E Terrebonne, P Michel, H Perrier, L Dahan, V Bourgeois, FK Akouz, E Soularue, VL Ly, Y Molin, T Lecomte, F Ghiringhelli, R Coriat, S Louafi, C Neuzillet, S Manfredi, D Malka,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading